Featured Research

from universities, journals, and other organizations

New agent may enhance effectiveness of radiotherapy

Date:
May 13, 2014
Source:
Manchester University
Summary:
The potential of a drug to improve the effectiveness of radiotherapy in stopping tumor growth has been demonstrated by scientists. There is increasing interest in using the body’s own immune system to attack tumor cells – a strategy that can be very effective without the side effects associated with conventional chemotherapy. Skin cancers, for instance, have been successfully treated using a topical cream, imiquimod, which recruits immune cells through a molecule known as toll-like receptor 7 (TLR7), a protein that recognizes foreign and potentially harmful material.

Scientists from The University of Manchester -- part of the Manchester Cancer Research Centre -- have demonstrated the potential of a drug to improve the effectiveness of radiotherapy in stopping tumor growth.

Related Articles


There is increasing interest in using the body's own immune system to attack tumor cells -- a strategy that can be very effective without the side effects associated with conventional chemotherapy.

Skin cancers have been successfully treated using a topical cream, imiquimod, which recruits immune cells through a molecule known as toll-like receptor 7 (TLR7), a protein that recognizes foreign and potentially harmful material.

Previously, researchers in Manchester have shown that they can also stimulate the immune system into generating an immune response against non-skin cancers by injecting an agent similar to TLR7 into the blood.

In collaboration with AstraZeneca and Dainippon Sumitomo Pharma, the Manchester group have looked at another molecule that activates TLR7, known as DSR-6434. Using mouse models of two different types of cancer, they investigated DSR-6434 on its own and in combination with radiotherapy and measured the effect on the primary tumor and the number of secondary tumors in the lungs.

Professor Ian Stratford, from Manchester Pharmacy School who, with Professor Tim Illidge, led the research published in the International Journal of Cancer, said: "We have already seen a strong immune system response from other immunotherapy agents in combination with radiation -- this new agent appears to be even more potent."

His team showed that administering DSR-6434 together with radiotherapy led to tumor shrinkage and increased long-term survival. They found that the combination treatment also reduced the occurrence of secondary lung tumors.

"It looks like there's good reason to use radiotherapy alongside immunotherapy agents in the treatment of solid tumors. These results strongly suggest that this sort of combination therapy should be evaluated in clinical trials with cancer patients," added Professor Stratford.


Story Source:

The above story is based on materials provided by Manchester University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Amy L. Adlard, Simon J. Dovedi, Brian A. Telfer, Erina Koga-Yamakawa, Charlotte Pollard, Jamie Honeychurch, Timothy M. Illidge, Masashi Murata, David T. Robinson, Philip J. Jewsbury, Robert W. Wilkinson, Ian J. Stratford. A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. International Journal of Cancer, 2014; DOI: 10.1002/ijc.28711

Cite This Page:

Manchester University. "New agent may enhance effectiveness of radiotherapy." ScienceDaily. ScienceDaily, 13 May 2014. <www.sciencedaily.com/releases/2014/05/140513092330.htm>.
Manchester University. (2014, May 13). New agent may enhance effectiveness of radiotherapy. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2014/05/140513092330.htm
Manchester University. "New agent may enhance effectiveness of radiotherapy." ScienceDaily. www.sciencedaily.com/releases/2014/05/140513092330.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins